One To Watch
RedHill Biopharma
Company Overview
A Tel Aviv-based specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, now reorienting its pipeline after divesting its Talicia H. pylori business to Apotex Health in August 2026. RedHill Biopharma (Nasdaq: RDHL) built its commercial presence around Talicia, the leading prescribed branded H. pylori therapy among US gastroenterologists, before monetizing that asset to refocus on its development-stage pipeline. The company retains programs spanning Crohn's disease, oncology, and gastrointestinal conditions.
Headquarters and Global Presence
RedHill is headquartered in Tel Aviv, Israel, and trades on the Nasdaq under the ticker RDHL. The company has historically maintained US commercial operations to support its gastroenterology products and retains a pipeline development footprint across multiple international clinical programs.
Founding and History
RedHill raised capital privately ahead of an initial public offering on the Tel Aviv Stock Exchange, and subsequently listed on Nasdaq, building a commercial GI franchise over several years. The company's trajectory has involved repeated portfolio reshaping: Movantik transitioned to Movantik Acquisition Co., an affiliate of HCR, in February 2023 in exchange for extinguishment of all of RedHill's debt obligations. The August 2026 Talicia divestment to Apotex Health marks the company's most significant recent strategic shift.
Therapy Areas and Focus
RedHill's development programs center on gastrointestinal disease and infectious disease, two areas with persistent unmet need and relatively limited oral therapeutic innovation. Its lead remaining pipeline asset targets Crohn's disease in a patient subset defined by Mycobacterium avium subspecies paratuberculosis (MAP) positivity, an etiology that most immunology-focused developers have not pursued. Opaganib spans oncology and anti-infective indications, giving the company an additional axis outside GI.
Technology Platforms and Modalities
RedHill's approach relies on fixed-dose oral combination therapies repurposing established antibiotic and small-molecule components in proprietary formulations. RHB-204 combines clarithromycin, rifabutin and clofazimine in a single fixed-dose oral regimen targeting MAP-positive Crohn's patients, addressing the bacterial hypothesis for at least a subset of the disease. Opaganib is a distinct modality: a first-in-class, orally administered selective inhibitor of sphingosine kinase-2, a lipid-signaling enzyme with roles in cancer proliferation, inflammation, and viral replication.
Key Pipeline and Programs
RHB-204 is a fixed-dose oral combination of clarithromycin, rifabutin and clofazimine being developed for Crohn's disease in patients who test positive for Mycobacterium avium subspecies paratuberculosis. RedHill has received positive FDA feedback on the pathway to approval for this indication, providing a regulatory anchor for the program. The company separately terminated a Phase III study of RHB-204 in non-tuberculous mycobacteria lung disease due to low accrual, narrowing the asset's clinical focus to Crohn's disease.
Opaganib (ABC294640) is a first-in-class oral sphingosine kinase-2 inhibitor with activity across anticancer, anti-inflammatory and antiviral pathways. It has been evaluated in oncology indications including prostate cancer and cholangiocarcinoma, as well as in COVID-19 patients with severe pneumonia. The breadth of the target biology gives opaganib a wide addressable indication set, though the oncology programs remain in earlier stages.
RHB-106 is an encapsulated bowel preparation that RedHill regained worldwide exclusive rights to after terminating its license agreement with Salix Pharmaceuticals. The program addresses gastrointestinal procedural preparation, a lower-profile but commercially viable niche.
Recent Developments
On 31 August 2026, RedHill announced the divestment of its 70% stake in the Talicia business to a subsidiary of Apotex Health for $18 million upfront plus up to $35 million in worldwide net sales milestone payments. Talicia had been FDA-approved since November 2019 and reached coverage of more than 202 million American lives as of March 2023, making its divestment a significant commercial exit. The transaction with Apotex continued a pre-existing relationship: the two companies had previously settled Movantik patent litigation.
Key Personnel
The research context does not name specific current executives by title. RedHill has historically been led through its Tel Aviv headquarters, with US commercial and clinical operations running alongside Israeli corporate functions.
Strategic Partnerships
The Apotex Health divestment is the company's most recent major transaction, generating up to $53 million in total potential proceeds. RedHill previously collaborated with Cosmo Pharmaceuticals on manufacturing for both Movantik and RHB-204, and held an exclusive license from Cosmo for US rights to Aemcolo (rifamycin) for traveler's diarrhea. The company also conducted a research collaboration with the US National Institute of Allergy and Infectious Diseases for potential Ebola treatment evaluation.
FAQ Section
The $18 million upfront payment plus up to $35 million in milestone payments from Apotex Health allows RedHill to monetize a commercial asset and redeploy capital toward its development pipeline. Talicia had reached more than 202 million covered American lives, so the divestment represents an exit at commercial maturity rather than early abandonment. The move follows the 2023 transfer of Movantik and signals a deliberate return to a development-focused operating model.
Mycobacterium avium subspecies paratuberculosis has long been proposed as a causative factor in a subset of Crohn's disease patients, analogous to the role of H. pylori in peptic ulcer disease. If the hypothesis holds in a defined MAP-positive population, antibiotic combination therapy could offer a fundamentally different mechanism from the immunosuppressants and biologics that dominate Crohn's treatment. The FDA's positive feedback on the approval pathway suggests regulators view the evidence base as sufficient to support a targeted development program.
Opaganib selectively inhibits sphingosine kinase-2, a lipid-signaling enzyme implicated in tumor cell survival, inflammatory signaling and viral replication. That mechanistic breadth is what has driven its evaluation across cholangiocarcinoma, prostate cancer and severe COVID-19 pneumonia. As a first-in-class oral agent, it carries both the upside of novelty and the validation risk of an unproven target in the clinic.
In the pivotal Phase III study, Talicia achieved an 84% H. pylori eradication rate in the intent-to-treat population, compared with 58% in the active comparator arm, results published in Annals of Internal Medicine. The FDA approved the omeprazole magnesium, amoxicillin and rifabutin combination in November 2019. It subsequently became the leading prescribed branded H. pylori therapy among US gastroenterologists, with insurance coverage extending to more than 202 million American lives by March 2023.
The retained pipeline spans gastroenterology and infectious disease, with a secondary oncology thread through opaganib. RHB-204 anchors the GI and infectious disease axis, targeting MAP-positive Crohn's patients with an oral antibiotic combination. RHB-106, a proprietary encapsulated bowel preparation for which RedHill holds worldwide rights, adds a procedural GI angle to the portfolio.
RedHill is now primarily a clinical-stage company, having divested its two main commercial products by August 2026. RHB-204 has received constructive FDA guidance on a Crohn's disease approval pathway, making it the most advanced near-term regulatory candidate. The company terminated the RHB-204 Phase III study in NTM lung disease due to accrual difficulties, so execution risk on future trials will be a recurring watchpoint.
The Talicia divestment closes out the commercial chapter and refocuses attention squarely on the pipeline.
Latest RedHill Biopharma News
Today's issue
| Headless Content Management with Blaze